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L’imagerie par résonance magnétique pour le diagnostic précoce 
de la maladie d’Alzheimer 
 





A major challenge for neuroimaging is to contribute to the early diagnosis of Alzheimer’s 
disease (AD). In particular, magnetic resonance imaging (MRI) allows detecting different 
types of structural and functional abnormalities at an early stage of the pathology. Anatomical 
MRI is the most widely used technique and provides local and global measures of atrophy. 
The recent diagnostic criteria of “MCI due to AD” include hippocampal atrophy which is 
considered a marker of neuronal injury. Advanced image analysis techniques generate 
automatic and reproducible measures both in the hippocampus and throughout the whole-
brain. Recent modalities such as diffusion-tensor imaging and resting-state functional MRI 




Un des enjeux majeurs de la neuroimagerie est de contribuer au diagnostic précoce de la 
maladie d’Alzheimer. L’imagerie par résonance magnétique (IRM) permet de détecter 
différents types d’altérations structurelles et fonctionnelles dès les premiers stades de la 
maladie. L’IRM anatomique est la technique la plus répandue et fournit des mesures 
d’atrophie cérébrale locales ou régionales. Les nouveaux critères de diagnostic de la maladie 
d’Alzheimer au stade des troubles cognitifs légers incluent l’atrophie hippocampique, qui est 
alors considéré comme un marqueur d’atteinte neuronale. Les techniques avancées d’analyse 
d’images génèrent des mesures automatiques et reproductibles à la fois dans l’hippocampe et 
dans l’ensemble du cerveau. Des modalités récentes telles que l’imagerie du tenseur de 
diffusion ou l’IRM fonctionnelle de repos fournissent des mesures complémentaires qui 
pourraient également contribuer au diagnostic précoce mais nécessitent d’être plus largement 
validées. 
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The increasing global prevalence and societal cost of Alzheimer’s disease (AD) explains the 
need for early diagnosis, in order to develop effective treatments able to stop the 
pathophysiological process. By integrating new methods for diagnosis based on both 
neuroimaging and biological markers, the diagnosis accuracy has improved, allowing 
diagnosis of MCI (mild cognitive impairment) due to AD. Among neuroimaging techniques, 
different types of magnetic resonance imaging (MRI) acquisitions may contribute to the early 
diagnosis of AD by detecting different structural and functional alterations. Anatomical MRI 
is the most widely used technique and allows measuring atrophy in various brain regions. 
Diffusion tensor imaging provides information on the integrity of white matter tracts. 
Functional MRI can be used to study alterations of functional connectivity. 
 
Anatomical Magnetic Resonance Imaging  
Besides its value to rule out others causes of cognitive dysfunction (normal pressure 
hydrocephalus, subdural hematoma e.g.), which remains an essential step in the clinical 
reasoning, MR imaging is now considered an essential part of AD diagnosis. In AD, 
anatomical MRI allows studying the presence of atrophy along with possible signs of 
associated vascular pathology. Brain atrophy can be assessed with 3D T1-weighted MRI 
acquisitions with approximately 1mm isotropic resolution. Anatomical MRI changes map 
accurately upstream to Braak stages of neurofibrillary tangle deposition and downstream to 
neuropsychological deficits. Neuropathologic studies in patients with AD showed that MRI 
alterations correlate with tau deposition, Braak stage, and neuronal counts (Vemuri et al. 
2008). Moreover, hippocampal atrophy is correlated with CSF tau markers (de Souza et al. 
2012) and with episodic memory deficit in AD patients (Sarazin et al. 2010).  
 
Medial Temporal Lobe atrophy (MTL) 
Hippocampal atrophy appears to be a robust biomarker of AD. Measurements of medial 
temporal lobe atrophy can distinguish AD from age-matched controls with overall sensitivity 
and specificity greater than 80% (Lehéricy et al. 2007). Medial temporal atrophy can be 
assessed in clinical routine by visual scales (Scheltens et al. 2002). Image segmentation 
methods have the advantage to provide automated and reproducible measures of hippocampal 
volume (Colliot et al. 2008). Hippocampal shape analysis has the potential to detect subtle 
alterations that are not reflected in global volumetric measurements (Gerardin et al. 2009). 
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Hippocampal atrophy is not specific to Alzheimer’s pathology and is described in 
other degenerative pathologies such as Parkinson disease (with or without dementia), vascular 
dementia (Laakso et al. 1996), dementia with Lewy Body (Hashimoto et al. 1998) and fronto 
temporal dementia (de Souza et al. 2013), or even in depression and “normal aging”. The 
overlap of hippocampal volume measures between AD and others medical conditions or aging 
limits its interpretation when considered without clinical data. 
In longitudinal MRI studies, the annual rate of hippocampal atrophy is higher in AD 
(from 2,2% to 5,9%) than in normal aging (from 0,2% to 1,7%) (Lehéricy et al. 2007). 
Moreover, MCI patients with fast cognitive decline would present a higher hippocampal 
atrophy rate than the patients remaining stable and the controls (Jack et al. 2000).  
The use of both MRI and biological tools could improve early diagnosis. For example, 
in a a cross-sectional study, the combination of CSF biomarkers and MRI provided better 
prediction than either source of data alone (Vemuri et al. 2009). Ultra-high field MRI, 
allowing in particular hippocampal subfield identification, is a promising research lead to 
increase the diagnostic accuracy of medial temporal measures (Mueller et al. 2011). 
 
Vascular component associated to AD  
Leucoaraiosis (white matter hyperintensities) and lacunar infarcts can be assessed using T2-
weighted and FLAIR (FLuid Attenuated Inversion Recovery) sequences. Varying degrees of 
small vessel disease, ischaemic-related white matter changes and one or more microinfarcts 
are frequently observed in patients presenting cognitive decline. T2*-weighted GRE 
sequences are used to study the presence of microbleeds, defined by small, well demarcated, 
hypointense, rounded lesions. In AD, the prevalence of microbleeds is of 15 to 30%, 
predominantly in the cortex, and should be due to frequent association between AD and 
cerebral amyloid angiopathy (CAA) (Cordonnier and van der Flier 2011). 
 
 
MRI based whole brain techniques 
Up to recently, the focus was made on the medial temporal structures, which are known to be 
an early site of tau pathology. With the development of automatic techniques such as MRI 
based whole brain volumetric and cortical thickness techniques, there is growing evidence of 




Voxel-Based Morphometry (VBM) 
VBM is an automatic technique (implemented for instance in the SPM software1) exploring 
morphological differences across the whole-brain. It analyzes local differences in tissue 
concentration using univariate statistical tests performed at each voxel of images which have 
been previously segmented and aligned to a common space.  
VBM studies have shown an early neocortical involvement with reduced grey matter 
in the posterior associate cortex and in the medial temporal lobe among MCI patients (Karas 
et al. 2004)(Hämäläinen et al. 2007). A greater GM loss in the medial temporal structures, in 
the posterior cingulate cortex and in the precuneus is thought to be predictive of conversion to 
AD dementia (Chételat et al. 2005). In addition, VBM could anticipate the rate of progression 
of AD. Patients with mild AD who will have a faster cognitive decline at 3 years already had 
more extensive cortical atrophy than patients with slower decline, especially in the medial 
occipitoparietal areas including the precuneus, which was not yet detected by clinical and 
neuropsychological assessment (Kinkingnéhun et al. 2008). 
However, the interpretation of the differences obtained with VBM may prove difficult 
and it is not always possible to distinguish between local volume and shape changes. VBM is 
a method for group analysis. However, it is possible to use voxel-based measures as features 
for individual classification (Vemuri et al, 2008; Cuingnet et al, 2011). 
 
Cortical thickness 
Cortical thickness may provide a more direct index of gray matter atrophy than VBM and 
thus allow a better distinction between volume and shape changes. Fully automatic 
approaches (implemented for instance in the Freesurfer2 software) provide local measures of 
thickness at each point of the cortical surface. Therefore, thinning patterns can then be 
analyzed by performing univariate tests in each of these points.  
Cortical thickness studies have shown that the medial temporal region, as well as the 
parietal association cortex and the prefrontal cortex, are significantly thinner in MCI patients 
(Singh et al. 2006), and longitudinal studies suggest that temporal (medial and inferior cortex, 
temporal pole) and parietal (superior parietal lobule) thinning allow differentiating the 
progressors from the non-progressors to Alzheimer’s dementia (Bakkour et al. 2009).  
Automatic classifiers based on cortical thickness or voxel-based measures have been 
designed to automatically distinguish individual patients. Their sensitivity and specificity 





reaches up to 80-95% for AD patients but is lower at the MCI stage (Cuingnet et al. 2011). 
 
Sulcal analysis 
A new method to measure morphological changes is based on the characteristics of cortical 
sulci. In particular, increased sulcal span is thought to be indicative of atrophy. An automatic 
approach (implemented in the Morphologist software of the Brainvisa platform3) is available 
to automatically segment and label up to 60 sulci per hemisphere. Conversely to VBM or 
cortical thickness techniques, it is not dependent on gray/white contrast that can be altered 
with age.  Furthermore, this technique does not rely on analysis in a common stereotaxic 
space (i.e. it does not assume point-to-point correspondences across subjects) but instead 
provides an individual model of cortical anatomy.  
 Changes in the parietal occipital fissure and in the intraparietal sulcus are found in 
patients with Alzheimer disease and MCI (Reiner et al. 2012), which is largely consistent 
with results obtained with other techniques. Furthermore, a recent longitudinal study indicates 
that sulcal measures (width of the superior temporal, superior frontal sulcus and the sylvian 
fissure) could predict the conversion of MCI patients (Liu et al. 2013). Further studies are 
necessary to establish the sensitivity and predictive power of these measures. 
 
Diffusion Tensor Imaging (DTI) 
DTI provides quantitative information about the orientation and the integrity of white matter 
tracts by measuring the diffusion of water molecules in the brain tissue. Diffusivity of water 
depends on the presence of microscopic structural barriers in tissue that alters the random 
motion of water molecules. Pathologic disruption of cell membranes, loss of myelin and 
axonal alteration decrease the movement restriction of water and therefore increases the mean 
diffusivity (MD). In amnestic MCI patients, two meta analyses have shown that MD is 
increased in various regions with the largest effect size in the hippocampus (Sexton et al. 
2011; Clerx et al. 2012). Furthermore, hippocampal MD is predictive of conversion to AD 
(Douaud et al. 2013). DTI also allows measuring fractional anisotropy (FA) corresponding to 
the degree of directionality of the diffusion along the axons of the WM. The loss of tract 
integrity decreases the FA at the MCI stage, mostly in the hippocampal, parahippocampal and 
cingular regions (Sexton et al. 2011; Clerx et al. 2012). However, DTI measures require 
further validation to be established as diagnostic biomarkers. 






Functional magnetic resonance imaging (fMRI) 
fMRI can be used to study brain activity through the measure of the BOLD contrast (Blood 
oxygen level dependent) which reflects neuronal activation. It allows investigating functional 
intrinsic connectivity of large-scale neural networks, at rest or during cognitive tasks. Here, 
we focus on resting-state fMRI. 
At rest, fMRI defines spatially distinct areas of the brain having synchronous BOLD 
fluctuations, which include the « default mode network » (DMN). This pattern of functional 
connectivity is active during resting periods and suspended during specific goal-directed 
behaviors (Raichle et al. 2001) and is altered in AD patients (Greicius et al. 2004). Several 
studies showed that the DMN is altered among patients with aMCI in the anterior medial 
frontal cortex and in the cingulate cortex compared to controls (Rombouts et al. 2005). A 
recent study showed high sensitivity and specificity for differentiating MCI and cognitively 
normal individuals, but the study included a small sample of patients (Chen et al. 2011). 
Furthermore, altered indices were significantly correlated with the results of cognitive tests 
(Chen et al. 2011). Finally, MCI subjects with disrupted connectivity in the DMN are shown 
to be at higher risk of converting to dementia within 4 years (Petrella et al. 2011). Further 




Anatomical MRI markers support earlier diagnosis and measurement of progression. Medial 
temporal lobe atrophy measured with high-resolution MRI is correlated with both tau 
deposition and neuropsychological deficits. MRI measures of hippocampal atrophy are 
considered as a marker of neuronal injury in the new criteria of MCI due to AD (Albert et al. 
2011). Whole-brain techniques that assess the overall pattern of atrophy without regional 
prior, provide complementary information which could improve early diagnosis. Finally, MRI 
provides new outcomes in clinical trials of potential disease-modifying therapies.  
DTI and resting-state fMRI may provide additional markers of neuronal injury but require 
further validation. Moreover, measures may be difficult to compare across different imaging 
centers. An important effort of standardization is thus necessary for establishing these new 
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